Table 1.
The effect of various treatments on SMARCA4-UT
| Reference | Age/sex | Smoking | TNM | PD-L1 (%) | Therapy(first-line to subsequent lines) | Outcome |
|---|---|---|---|---|---|---|
| Iijima et al. (2020) | 76/M | Current smoker (49 pack-years) | IV | 0 | Carboplatin and paclitaxel | PR to bone metastasis |
| Open surgery and radiation for bone | – | |||||
| Carboplatin and etoposide | PD | |||||
| Nivolumab | 22 months PR to August 2019 | |||||
| Takada et al. (2019) | 70/F | Unknown | IV | > 60 | Pembrolizumab for 8 cycles | PR |
| Henon et al. (2019) | 58/F | Unknown | IV | 0 | Radiotherapy and carboplatin and paclitaxel | – |
| Pembrolizumab | 11 months PR to March 2019 | |||||
| Kawachi et al. (2021) | 73/F | Current smoker (53 pack-years) | IVB | 40 | ABCP for 3 cycles then AB maintenance | PR after 2 cycles of ABCP No PD for 17 months |
| 59/M | Current smoker (39 pack-years) | IVB | 0 | ABCP for 3 cycles then AB maintenance | PR after 2 cycles of ABCP No PD for 10 months | |
| 64/F | Past smoker (44 pack-years) | IVB | 80 | ABCP for 4 cycles | PR after 3 cycles of ABCP | |
| Brain Radiotherapy then AB maintenance | No PD for 2 months | |||||
| Kunimasa et al. (2021) | 51/M | Current smoker (22.5 pack-years) | IVA | 0 | ABCP for 6 cycles | PR |
| Conversion surgery | No recurrence for 9 months | |||||
| Shi et al. (2022) | 50/M | Current smoker (36 pack-years) | IVA | 90 | Tislelizumab for 7 cycles | 7 cycles of PR to August 2022 |
| Anzic et al. (2021) | 41/M | Current smoker | IV | 100 | Pembrolizumab for 8 cycles | mixed response |
| Pembrolizumab and ipilimumab for 4 cycles | mixed response | |||||
| Carboplatin and paclitaxel for 2 cycles | – | |||||
| Radiotherapy with doxorubicin and ifosfamide for 6 cycles | died in August 2020 | |||||
| Dong et al. (2024) | 56/M | smoker (Brinkman index: 600) | IB | 5 | Surgury | PD after 3 months |
| TEP for 3 cycles then tislelizumab maintenance | No PD for 9 months | |||||
| Takei et al. (2024) | 40/M | Current smoker(2 pack per day for 25 years) | IIB | 1 | Cisplatin, vinorelbine and radiation | PR |
| Conversion surgery | PD after postoperative day 36 | |||||
| ABCP for 4 cycles | PD after 4 cycles of ABCP | |||||
| Takei et al. (2024) | 74/M | Current smoker(1 pack per day for 54 years) | IIIA | 0 | Carboplatin, paclitaxel and radiation | PR |
| Conversion surgery | No PD for 12 months |
ABCP, Atezolizumab, bevacizumab, carboplatins and paclitaxel; TEP, Tislelizumab, etoposide and cisplatin; AB, Atezolizumab and bevacizumab; PR, Partial response; PD, Progressive disease